← FDA DRUG APPROVALS

FDA ANDA · ANDA219166

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION

brimonidine tartrate and timolol maleate

Sponsor: GLAND

APPLICATION
ANDA219166
TYPE
ANDA
ORIGINAL APPROVAL
2026-06-11
LATEST ACTION
2026-06-11
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Prescription

Products

BRIMONIDINE TARTRATE AND TIMOLOL MALEATEPrescription
BRIMONIDINE TARTRATE 0.2%, TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS · OPHTHALMIC

Approval history

2026-06-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →